Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2010-05, Vol.24 (5), p.1099-1101
Hauptverfasser:	Puissant, A, Dufies, M, Raynaud, S, Cassuto, J-P, Auberger, P
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1059/602 631/80/642/1624 631/80/82 692/699/67/1990/283/1896 Antineoplastic Agents - adverse effects Benzamides Biological and medical sciences Cancer Research Cathepsin B - antagonists & inhibitors Cathepsin B - genetics Cathepsin B - metabolism Cathepsins Chronic myeloid leukemia Critical Care Medicine Drug Resistance, Neoplasm Drug therapy Genetic aspects Hematologic and hematopoietic diseases Hematology Humans Imatinib Imatinib Mesylate Intensive Internal Medicine letter-to-the-editor Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Life Sciences Lysosomes Lysosomes - metabolism Lysosomes - pathology Medical sciences Medicine Medicine & Public Health Myeloid leukemia Oligopeptides - pharmacology Oncology Physiological aspects Piperazines - adverse effects Protein-Tyrosine Kinases - antagonists & inhibitors Pyrimidines - adverse effects RNA, Small Interfering - pharmacology Tumor Cells, Cultured
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!